How Amgen Makes its Money: Revenue Breakdown
A breakdown of Amgen (AMGN) financials. See how Amgen makes money from Enbrel (autoimmune), Prolia (bone health), XGEVA (bone metastases), and more using their 2024 annual report.
How Does Amgen Make its Money?
Amgen is one of the world’s largest biotechnology companies, with a portfolio of blockbuster drugs spanning oncology, bone health, cardiovascular disease, inflammation, and rare diseases. The company significantly expanded in 2023 through its $28 billion acquisition of Horizon Therapeutics, adding rare disease therapies including TEPEZZA (thyroid eye disease) and KRYSTEXXA (chronic gout) to an already diversified portfolio.
Amgen is also at center stage in the hottest area in pharma: obesity. Its experimental drug MariTide is a next-generation obesity treatment that could compete with Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy. MariTide uses a novel antibody approach that could differentiate it from current GLP-1 receptor agonists, making Amgen one of the most closely watched companies in biotech.
Amgen (AMGN) Business Model
Amgen operates in the biotechnology sector, generating revenue from patented biologic and small-molecule drugs. The company invests approximately $5.5B annually in R&D and commercializes drugs globally through its own sales force (~25,000 employees). This breakdown uses data from Amgen’s 2024 fiscal year filings with the SEC.
What makes Amgen’s business model distinctive is its biosimilar portfolio — Amgen is one of the few large pharma companies that both markets original biologics AND sells biosimilar versions of competitors’ drugs (including biosimilars of Humira, Avastin, Herceptin, and others). This dual approach generates revenue from both innovator products with patent protection and biosimilar products that capture share from off-patent biologics.
Amgen Competitors
Amgen’s key competitors and comparable public companies in the biotechnology sector include Eli Lilly, Novo Nordisk, Gilead Sciences, and Pfizer. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Amgen stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Segment | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Prolia (bone health) | $4,200M | $3,900M | +7.7% |
| Enbrel (autoimmune) | $3,200M | $3,700M | -13.5% |
| Repatha (cholesterol) | $2,600M | $1,900M | +36.8% |
| XGEVA (bone metastases) | $2,200M | $2,100M | +4.8% |
| EVENITY (osteoporosis) | $1,500M | $1,100M | +36.4% |
| TEZSPIRE (asthma) | $1,300M | $800M | +62.5% |
| Horizon portfolio & Other | $18,400M | $15,700M | +17.2% |
| Total Revenue | $33,400M | $28,200M | +18.4% |
Prolia — 13% of Revenue
Prolia ($4.2B) is a biologic injection (denosumab) for osteoporosis, administered every six months. It’s the most prescribed branded osteoporosis treatment in the U.S. and continues to grow steadily (+7.7%) as the aging population drives higher diagnosis rates. Prolia is a key cash cow for Amgen, generating high margins with a well-established commercial infrastructure.
Enbrel — 10% of Revenue
Enbrel ($3.2B) is an anti-TNF biologic for rheumatoid arthritis, psoriasis, and other autoimmune conditions. Revenue declined 13.5% due to intensifying biosimilar competition — though Enbrel has held up better than many expected, thanks to the complexity of manufacturing large-molecule biologics and patient/physician inertia in switching established therapies. Enbrel’s decline will continue but is expected to be gradual rather than a cliff.
Repatha — 8% of Revenue
Repatha ($2.6B) is a PCSK9 inhibitor that dramatically lowers LDL cholesterol and reduces cardiovascular events. Revenue surged 36.8%, making it one of Amgen’s fastest-growing products. Growth is being driven by broader insurance coverage, updated clinical guidelines recommending PCSK9 inhibitors earlier in treatment, and increasing awareness of the cardiovascular risk reduction benefits beyond just cholesterol lowering.
Horizon Portfolio & Other — 55% of Revenue
This large category ($18.4B) includes the Horizon Therapeutics acquisition portfolio (TEPEZZA for thyroid eye disease, KRYSTEXXA for gout), biosimilars (AMJEVITA/biosimilar Humira, MVASI/biosimilar Avastin), Otezla (oral psoriasis), Blincyto (blood cancer), Lumakras (lung cancer), and many other products. The 17.2% growth reflects a full year of Horizon revenues plus strong performance from newer launches.
Amgen (AMGN) Income Statement
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $33,400M | $28,200M |
| Gross Profit | $21,600M | $19,900M |
| Operating Income | $6,800M | $5,300M |
| Net Income | $5,700M | $4,800M |
Financial data sourced from Amgen SEC Filings.
Amgen (AMGN) Key Financial Metrics
- Gross Margin: 64.7% — Somewhat lower than pure pharma peers, partly because Amgen’s biosimilar products carry lower margins than innovator drugs, and the Horizon integration temporarily impacts cost structure.
- Operating Margin: 20.4% — Solid but compressed by the Horizon acquisition’s integration costs and amortization of acquired intangible assets. Adjusted operating margins are closer to 45-50%.
- Revenue Growth: 18.4% — Very strong, boosted by the first full year of Horizon Therapeutics revenue contributions plus organic growth in Repatha, EVENITY, and TEZSPIRE.
Is Amgen Profitable?
Yes, Amgen is profitable, reporting $5.7B in net income on $33.4B in revenue. Profitability improved 18.8% year-over-year on strong revenue growth. However, GAAP earnings significantly understate Amgen’s cash-generating ability — the company generates ~$12-13B in adjusted earnings and ~$11B in free cash flow annually. The difference is driven by large non-cash amortization charges from the Horizon and other acquisitions. Amgen uses its strong cash flow to fund a generous dividend ($4.5B annually), share buybacks, and ongoing M&A.
Amgen (AMGN): What to Watch
- MariTide obesity trial results — Amgen’s obesity drug candidate is the single biggest swing factor for the stock. Positive Phase 2/3 data could position Amgen as a major player in the $100B+ obesity market, while disappointing results would be a significant setback.
- TEPEZZA growth trajectory — Acquired through Horizon, TEPEZZA is the only FDA-approved treatment for thyroid eye disease. Reaching $4-5B in peak sales would validate the Horizon acquisition price.
- Enbrel erosion pace — Biosimilar competition is intensifying, but Enbrel has shown more resilience than expected. Whether the decline accelerates or remains gradual impacts Amgen’s overall revenue trajectory.
- Debt reduction — The Horizon acquisition left Amgen with ~$60B in debt. Deleveraging through free cash flow while maintaining the dividend and investing in the pipeline is a capital allocation balancing act.
- Biosimilar portfolio expansion — Amgen’s biosimilar business is scaling and could become a multi-billion dollar franchise as more branded biologics lose patent protection in the coming years.
Amgen (AMGN) Financial Summary
Amgen (AMGN) is a biotechnology company that generated $33.4B in total revenue in fiscal year 2024, growing 18.4% year-over-year driven by the Horizon Therapeutics acquisition and strong organic growth. The company earned $5.7B in net income while investing in its MariTide obesity drug candidate. For a deeper look at Amgen’s revenue breakdown, business segments, and financial performance, review the detailed analysis above.
Weekly Company Breakdowns — Visualized
See how top companies actually make money. Visual revenue breakdowns delivered free every week.